Abstract Primary biliary cirrhosis (PBC) is characterized by chronic destructive cholangitis, which is associated with the reduced expression of an anti-inflammatory molecule, peroxisome proliferator-activated receptor-c (PPARc), in intrahepatic bile ducts. We previously demonstrated the anti-inflammatory effects of PPARc ligands using cultured human biliary epithelial cells. In this study, we evaluated the effectiveness of PPARc ligand against peribiliary inflammation in vivo. As an animal model of PBC, we used MRL/lpr mice in which a PBC-like cholangitis occurs naturally. Anti-inflammatory effects of the intraperitoneal administration of a PPARc ligand, the prostaglandin D metabolite 15-deoxy-D 12,14 -prostaglandin J2 (15d-PGJ2), were evaluated. In untreated mice, portal inflammation including cholangitis was found to some degree in the majority of portal tracts. In mice given a high-dose group, the degree of portal inflammation was significantly reduced and mice mostly lacking portal inflammation and cholangitis were also found. T cell numbers in portal tracts were markedly decreased in the high-dose group, compared with controls, whereas there was no significant difference in terms of B cells and macrophages. This study is the first to assess the therapeutic potential of a PPARc ligand against portal inflammation including cholangitis. Anti-inflammatory effects of PPARc ligands may prevent the progression of cholangiopathy in PBC patients.
Introduction
Primary biliary cirrhosis (PBC) is characterized by the progressive loss of bile ducts, mainly interlobular bile ducts [1, 2] . Infectious and xenobiotics components and abnormal immune responses are implicated in the etiopathogenesis of PBC [3] [4] [5] [6] [7] [8] . Our previous study showed that biliary epithelial cells (BECs) of the intrahepatic bile ducts possess an innate immune machinery consisting of bacterial recognition molecules, Toll-like receptors (TLRs), and can respond to lipopolysaccharide (LPS) followed by nuclear factor-jB (NF-jB) and inflammatory cytokines in BECs [9, 10] . Under physiological conditions, however, the intrahepatic biliary epithelium lacks any inflammatory reactions in vivo, though several pathogen-associated molecular patterns (PAMPs) including bacterial DNA and LPS exist in bile [9, 11] , suggesting that BECs possess the capacity to attenuate cytokine gene expression related to the innate immune system. We have reported that peroxisome proliferator-activated receptor c (PPARc), a nuclear receptor superfamily of ligand-activated transcription factors involved in lipid metabolism and anti-inflammatory activities, was down-regulated in the damaged bile ducts of PBC patients and speculated that increased susceptibility to biliary innate immunity is associated with the pathogenesis of cholangiopathy in PBC [12] .
In addition to the biliary epithelial cells of PBC, a reduction of PPARc expression in the colonic epithelial mucosa is reportedly associated with the pathogenesis of inflammatory bowel diseases (IBD) [13] [14] [15] [16] . Furthermore, the expression of PPARc is affected by the commensal intestinal flora and ligands (agonists) for PPARc can attenuate colitis in IBD-model mice, supporting the notion that PPARc ligands may have salutary effects on IBD [14, 16] . As for anti-inflammatory activities, the activation of PPARc by its ligands is shown to inhibit the expression of pro-inflammatory cytokines, the induction of which is mediated via NF-jB and mitogen activated protein kinase (MAPK) [17, [19] [20] [21] [22] [23] . Several PPARc ligands have been identified, including the prostaglandin D metabolite 15-deoxy-D 12,14 -prostaglandin J2 (15d-PGJ2) and thiazolidinedione derivatives. Our previous study demonstrated that 15d-PGJ2 treatment attenuated LPS-induced NF-jB activation and also TNF-a production via an NF-jBdependent pathway using cultured intrahepatic cholangiocarcinoma cells and biliary epithelial cells [12] .
In this study, we examined anti-inflammatory effects of PPARc ligands in vivo using MRL/lpr mice with a naturally occurring PBC-like cholangitis to clarify possible therapeutic targets in biliary inflammation.
Materials and methods

PPARc ligand
An endogenous ligand, 15d-PGJ2 (diluted by DMSO, Calbiochem, Darmstadt, Germany), was used as a PPARc ligand.
Animals
MRL/lpr mice bearing the lymphoproliferative gene lpr spontaneously develop severe autoimmune diseases including a systemic lupus erythematosus (SLE) and CNSDC-like cholangitis and produce an anti-mitochondrial antibody [24] . This strain was used here as an animal model for autoimmune-mediated cholangitis similar to PBC. A total of 20 18-week-old MRL/lpr mice (male/female = 10/10) were purchased from Japan SLC, Inc. (Shizuoka, Japan).
Animal treatments
15-deoxy-D 12,14 -prostaglandin J2 was administered at low (400 lg/kg/day) and high (1,000 lg/kg/day) doses (5 mice each) for 3 weeks by intraperitoneal injection. The control group (n = 10) received only vehicle (DMSO). After the animals were killed, major organs were obtained and 4-lmthick sections of neutral formalin-fixed paraffin-embedded tissues were prepared for routine histologic observation and immunohistochemistry. The manipulation of these mice was done according to the Guidelines for the Care and Use of Laboratory Animals at the Takaramachi Campus of Kanazawa University (Approved Number, 050273).
Histological examination
To evaluate the anti-inflammatory effect of PPARc, major organs were examined histologically. For the liver, ten representative portal tracts containing interlobular bile ducts were chosen and portal inflammation including cholangitis in each was semiquantitatively evaluated as no or mild (score 0), moderate (score 1), or severe (score 2).
Immunohistochemistry
The deparaffinized and rehydrated sections used for studying CD3, and monocytes/macrophages and CD8 were treated with proteinase K and trypsin, respectively, while those used for CD79a were microwaved in 10 mM citrate buffer for 20 min in a microwave oven. Following the blocking of endogenous peroxidase, these sections were incubated at 4°C overnight with antibodies against CD3 (rat IgG, 10 lg/ ml, Millipore Headquarters, Billerica, MA), CD8 (rat IgG1, 2.5 lg/ml, Chemicon, Tokyo), CD79a (rabbit IgG, 1.0 lg/ ml, Abcam Japan, Tokyo), and macrophage/monocyte (rat IgG, 2.5 lg/ml, BMA Biomedicals, Augst, Switzerland) and then at room temperature for 1 h with a Simple Staining Kit (Nichirei, Tokyo). After a benzidine reaction, sections were lightly counterstained with hematoxylin. As a negative control, isotype-matched immunoglobulin was used as the primary antibody.
Statistical analysis
Data were analyzed using Welch's t test; p \ 0.05 was considered statistically significant. 
Results
Histology of MRL/lpr mice
Variation in the incidence and degree of systemic lymphadenopathy, sialoadenitis, nephritis, pneumonia, arthritis, and hepatitis including cholangitis was found in MRL/ lpr mice. In particular, sialoadenitis always occurred and the inflammation was extensive and destructive in most mice. In the liver, portal inflammation involving mononuclear cells was detected and portal tracts were cellularly enlarged. Moreover, chronic cholangitis resembling CNSDC was also found at varying degrees (Fig. 1) .
Effect of 15d-PGJ2
In the group injected intraperitoneally with a low dose of 15d-PGJ2, portal inflammation including cholangitis in interlobular bile ducts remained, the incidence and degree being similar to those in the controls (vehicle) (Fig. 2c, d) . However, in the high-dose group, the portal inflammation and cholangitis were attenuated and their incidence and degree were significantly reduced (Fig. 2a) . Almost no portal inflammation or cholangitis was found in one of the five mice in the high-dose group (Fig. 2b) . Semiquantitative evaluation demonstrated that inflammation was improved in the high-dose group (Fig. 3) , but not low-dose group. For sialoadenitis and pancreatitis, although some inflammatory damage remained, it was significantly less severe in the low-dose as well as high-dose group. For glomerulonephritis, there was no significant anti-inflammatory effect in 15d-PGJ2-injected mice.
Analysis of inflammatory cells in portal tracts
To analyze the population of inflammatory cells in portal tracts of MRL/lpr mice and changes in the high-dose group, T cells, B cells, and macrophages were examined by (Figs. 4, 5) . In particular, the number of CD3-positive T cells was clearly decrease in 15d-PGJ2-administered mice and this reduction was significant in portal tracts without inflammation (Fig. 4) . However, a few CD8-positive T cells were found irrespective of 15d-PGJ2-treatment, indicating the decrease of CD3-positive T cells is caused by that of CD4-positive T cells. A summary of the population of inflammatory cells in portal tracts is given in Table 1 .
Discussion
We reported previously that PPARc showing anti-inflammatory effects was constantly expressed in human biliary epithelial cells of intrahepatic small bile ducts including interlobular bile ducts and cultured human biliary epithelial cells [27] . Moreover, the expression of PPARc has been reported to be down-regulated by a Th1-dominant cytokine milieu and reduced in the damaged bile ducts of PBC patients [27] . Based on these findings, we speculated that a Th1-dominant periductal cytokine milieu caused by CD4-positive T cells, following the reduction of PPARc expression and increased susceptibility to several proinflammatory factors including innate immune responses is closely associated with the pathogenesis of cholangiopathy in PBC. Studies in vitro have shown that functional PPARc ligands suppress inflammatory responses by limiting the production of cytokines and chemokines secreted from macrophages and epithelial cells [16, [28] [29] [30] . PPARc ligands are divided into endogenous types and thiazolidinedione derivatives. As one of the former, the prostaglandin D metabolite 15d-PGJ2 is well known and reported to attenuate the activation of NF-jB, a master regulator of inflammation, by preventing the phosphorylation of its inhibitor protein (I-jB) [31] . Our recent study demonstrated that 15d-PGJ2 treatment attenuated LPS-induced NF-jB activation and also TNF-a production via an NF-jB-dependent pathway in cultured intrahepatic cholangiocarcinoma cells and biliary epithelial cells [9, 27] .
In this study, to verify whether PPARc ligands show anti-inflammatory effects against portal inflammation including cholangitis in vivo, we used autoimmunity-prone mice, MRL/lpr. These mice have lymphoproliferative lesions caused by a deficiency of Fas (CD95) and spontaneously develop various forms of autoimmune disease in the same individuals, including glomerulonephritis, polyarteritis, arthritis and sialoadenitis associated with excessive production of autoantibodies [25] . Therefore, MRL/lpr mice have not only been used as a model for the study of SLE, but also reported as a potentially suitable animal model of PBC [24, 26] . Although several clinical features including serum levels of total bilirubin and hepatobiliary enzymes including alanine aminotransferase (ALT), leucine aminopeptidase (LAP), and gamma-glutamyl transpeptidase (G-GTP) are incompatible with PBC, the serological and histopathological features including antimitochondrial antibody (AMA), cholangitis, and bile duct loss, indicate that MRL/lpr mice can be used as an experimental immune-mediated cholangitis model for PBC [24, 26] . This study demonstrated that the administration of 15d-PGJ2 (high-dose) could attenuate the degree of portal inflammation in MRL/lpr mice. Because the incidence of cholangitis was originally low and individual differences were significant, the anti-inflammatory effect was considered relatively mild as shown in Fig. 3 . However, the cholangitis and portal inflammation were completely absent in the mice given a high-dose of 15d-PGJ2, suggesting an anti-inflammatory effect of PPARc on portal inflammation. Moreover, an evaluation of the proportion of inflammatory cells in portal tracts revealed as significant reduction in T cells in PPARc-administered mice. Moreover, although we could not directly confirm the decrease of CD4-positive T cells, because of no antibodies against mouse CD4 which are commercially available and usable for formalin-fixed, paraffin-embedded section, the decrease of CD3-positive T cells was speculated to be caused by that [32] . Therefore, because the PPARc ligand had anti-inflammatory effects caused by the attenuation of CD4-positive T lymphocytes, it is likely to show as anti-inflammatory effect on cholangiopathy in PBC patients as well as MRL/lpr mice.
In addition to cholangitis, sialoadenitis and pancreatitis in MRL/lpr mice were also improved by the low dose as well as high dose of 15d-PGJ2, suggesting that the sialoadenitis and pancreatitis are closely associated with PPARc-dependent mechanism and show more susceptibility to PPARc ligand, compared with cholangitis. However, as for the severity of glomerulonephritis, there was no significant anti-inflammatory effect in 15d-PGJ2-injected mice. In SLE, the deposition in kidney tissue of immune complexes and their interaction with macrophages is thought to trigger the inflammatory response leading to glomerulonephritis. Moreover, macrophage-dependent destruction in MRL/lpr mice is demonstrated in the pathogenesis of glomerulonephritis [33] . As shown in Table 1 concerning the immunohistochemistry, the inflammation of monocyte/macrophage was less attenuated by the 15d-PGJ2 treatment, compared with that of T cells, speculating that 15d-PGJ2 offers little benefit to the macrophage-dependent destruction such as glomerulonephritis in MRL/lpr mice.
Other PPARc ligands include rosiglitazone, pioglitazone, troglitazone, and ciglitazone. Pioglitazone has been recently administered for diabetic mellitus and non-alcoholic steatohepatitis. Troglitazone had been used to treat diabetic mellitus and in one notable case, improved liver dysfunction in a patient with AMA-negative PBC [34] . It is no longer used because of its severe hepatotoxicity, but several effects of Troglitazone on inflammatory bowel diseases, carcinogenesis in the colon, diabetic mellitus, chronic pancreatitis, and sepsis in animal models have been reported [18, [35] [36] [37] . In this study, in addition to the anti-inflammatory activity of PPARc in cultured human biliary epithelial cells, we demonstrated effected in vivo using MRL-lpr mice. This study is the first to assess the therapeutic role of a PPARc ligand in inflammatory biliary diseases, particularly PBC. PPARc ligands are potentially a new tool to restrain the progression of cholangiopathy in PBC patients. 
